Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP296005.RAikR8Z-iL4DnDpytXtQRmeOLlM6L2LO2LaKVv-hanVV0130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP296005.RAikR8Z-iL4DnDpytXtQRmeOLlM6L2LO2LaKVv-hanVV0130_provenance.
• NP897474.RAv5RfjdlyO3mElqsnqfslyjdHOICWjw89iJDmwpNxaNU130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP897474.RAv5RfjdlyO3mElqsnqfslyjdHOICWjw89iJDmwpNxaNU130_provenance.
• NP634350.RAF6qj3ruRprQ9eT8J3wROlF5Vrg_1SkZZsBSEOPzOLEI130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP634350.RAF6qj3ruRprQ9eT8J3wROlF5Vrg_1SkZZsBSEOPzOLEI130_provenance.
• NP300327.RAVPx8sBXeArBg2wGrTKOr2kbFk1pWy-1TQTgQfTUzcic130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300327.RAVPx8sBXeArBg2wGrTKOr2kbFk1pWy-1TQTgQfTUzcic130_provenance.
• NP306130.RAe_VemfXuIun7NrQe4hfSjrZtCIcuMinOZl1eBKp2Hko130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP306130.RAe_VemfXuIun7NrQe4hfSjrZtCIcuMinOZl1eBKp2Hko130_provenance.
• assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP660333.RA5-VfzthLjdHjJyBastfjdaKm72LSJOoY9MNB-VTA8A0130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660333.RA5-VfzthLjdHjJyBastfjdaKm72LSJOoY9MNB-VTA8A0130_provenance.
• NP660338.RA1puu291xjp5el0VI8yqVqp6i9nVUjxuU0zt2Kt8kRhk130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660338.RA1puu291xjp5el0VI8yqVqp6i9nVUjxuU0zt2Kt8kRhk130_provenance.
• NP660340.RAyEABql8B2Gh58Y8R_ARsMDdBtKo8SBjh1lKXn1vTtWE130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660340.RAyEABql8B2Gh58Y8R_ARsMDdBtKo8SBjh1lKXn1vTtWE130_provenance.
• NP300390.RAKoQmVQsj1VfP9TFR1IsSdmqp0ArSl98MldRRPIH-5_A130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300390.RAKoQmVQsj1VfP9TFR1IsSdmqp0ArSl98MldRRPIH-5_A130_provenance.
• NP305698.RAKT2Xd7_4fNzuMzKqGmwQ8tZmkSrJm-KzjIxRl7gtSHA130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP305698.RAKT2Xd7_4fNzuMzKqGmwQ8tZmkSrJm-KzjIxRl7gtSHA130_provenance.
• NP300345.RAkKvSZALIi5YvsjBH8v2kasWbkbXK9iBz4G0Gq26JEVI130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300345.RAkKvSZALIi5YvsjBH8v2kasWbkbXK9iBz4G0Gq26JEVI130_provenance.
• NP660334.RAte3lYTl0B_VMBJ3lIxpBTC4Nueo0vmn_H5GIgs0kyh8130_assertion description "[Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660334.RAte3lYTl0B_VMBJ3lIxpBTC4Nueo0vmn_H5GIgs0kyh8130_provenance.